ATXS Astria Therapeutics Inc
Price (delayed)
$11.12
Market cap
$627.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.38
Enterprise value
$546.03M
Highlights
Astria Therapeutics's equity has surged by 73% YoY but it has decreased by 6% QoQ
The net income has dropped by 90% year-on-year and by 14% since the previous quarter
ATXS's quick ratio is down by 35% from the previous quarter and by 30% YoY
Key stats
What are the main financial stats of ATXS
Market
Valuations
Earnings
Shares outstanding
56.43M
Market cap
$627.45M
Enterprise value
$546.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$93.24M
EBITDA
-$93.24M
Free cash flow
-$80.71M
Per share
Balance sheet
Liquidity
EPS
-$2.38
Free cash flow per share
-$1.43
Book value per share
$6.32
Revenue per share
$0
TBVPS
$6.51
Total assets
$367.99M
Total liabilities
$20.91M
Debt
$5.79M
Equity
$347.08M
Working capital
$341.52M
Debt to equity
0.02
Current ratio
21.87
Quick ratio
21.67
Net debt/EBITDA
0.87
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-31.2%
Return on equity
-32.6%
Return on invested capital
-62.2%
Return on capital employed
-26.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATXS stock price
How has the Astria Therapeutics stock price performed over time
Intraday
-3.14%
1 week
-9.08%
1 month
10.43%
1 year
24.66%
YTD
44.79%
QTD
22.2%
Financial performance
How have Astria Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$107.39M
Net income
-$93.24M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 94% year-on-year and by 15% since the previous quarter
The net income has dropped by 90% year-on-year and by 14% since the previous quarter
Growth
What is Astria Therapeutics's growth rate over time
Valuation
What is Astria Therapeutics stock price valuation
P/E
N/A
P/B
1.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Astria Therapeutics's equity has surged by 73% YoY but it has decreased by 6% QoQ
The P/B is 35% higher than the 5-year quarterly average of 1.3 and 17% higher than the last 4 quarters average of 1.5
Efficiency
How efficient is Astria Therapeutics business performance
The ROIC has increased by 25% QoQ but it has decreased by 10% YoY
Astria Therapeutics's return on equity has decreased by 24% YoY
ATXS's ROA is down by 23% YoY
Dividends
What is ATXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATXS.
Financial health
How did Astria Therapeutics financials performed over time
ATXS's total liabilities has soared by 89% since the previous quarter
ATXS's total assets has soared by 78% YoY but it is down by 2.9% QoQ
Astria Therapeutics's debt is 98% lower than its equity
Astria Therapeutics's equity has surged by 73% YoY but it has decreased by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.